Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Novo Nordisk A/S has finalized a groundbreaking deal to address the rising demand for its weight-loss drug, Wegovy, and diabetes treatment, Ozempic. In a significant move, Novo's largest shareholder has acquired Catalent Inc., one of the world's leading drug-manufacturing companies, for a staggering $16.5 billion, including debt.
As per Reuters, this three-way arrangement will see the Danish pharmaceutical company pay $11 billion to obtain three of Catalent's manufacturing facilities, fortifying its supply chain and overcoming recent shortages of Wegovy and Ozempic.
Fierce Competition and the Emergence of Zepbound
Novo Nordisk races to enhance its supply chain but faces fierce competition from Eli Lilly & Co. Lilly's obesity shot, Zepbound, was recently approved and is expected to become the highest-selling drug in history.
Yahoo pointed out that patient trials have demonstrated greater weight loss results with Lilly's drug compared to anything Novo has developed thus far. With this in mind, Novo's strategic acquisition of Catalent aims to solidify its market position and fend off the intensifying rivalry.
Novo Nordisk's purchase of Catalent has garnered support from Elliott Investment Management, an activist investor with a stake in the US company. The agreement values Catalent at $63.50 per share in cash, reflecting a 17% premium to its Friday closing price. However, Catalent faced manufacturing issues in September 2021, affecting its production of COVID-19 vaccines for Moderna Inc. and one of Regeneron Inc.'s top-selling drugs.
Novo Nordisk's Strategic Move to Meet Surging Demand Boosts its Market Value
Shares of Novo Nordisk have been surging alongside the increasing demand for its obesity and diabetes drugs, reaching a record high. With a market value exceeding $520 billion, Novo is now Europe's largest publicly traded company. Meanwhile, Catalent's stock rose by up to 10% in New York as news of the deal emerged.
This monumental $16.5 billion agreement between Novo Nordisk and Catalent marks the largest deal ever for companies and their controlling shareholder, Novo Holdings A/S. Novo Holdings currently controls 77% of the voting rights in the Danish drugmaker, further solidifying its influence and position in the pharmaceutical industry.
Photo: Novo Nordisk Newsroom
